Accueil > Actualité
Actualite financiere : Actualite bourse

Roche: priority review in Duchenne myopathy

( - Sarepta Therapeutics announced on Monday that the US FDA haz granted a priority review to its marketing application for SRP-9001, an experimental gene therapy for boys with Duchenne muscular dystrophy that the company is developing in collaboration with Roche.

In its statement, the US biotech said the health agency has set a target date of 29 May 2023 for the product's approval.

In December 2019, Roche entered into a partnership with Sarepta for the moxeparvovec delandistrogen gene therapy (SRP-9001) aimed at accelerating its availability outside the US.

Copyright (c) 2022 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.